Having identified OX40 and 4–1BB as potential immunotherapy targets of relevance to UPS patients who fail to respond to radiotherapy or surgery, we wished to further profile their expression to increase our understanding of the immune contexture of sarcoma. Here, TNFRSF4 is linked to undifferentiated pleomorphic sarcoma.